GF Fund Management
BDTX icon

GF Fund Management’s Black Diamond Therapeutics BDTX Stock Holding History

GF Fund Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.43K Buy
1,290
+105
+9% +$206 ﹤0.01% 596
2026
Q2 		$2.19K Sell
1,185
-87
-7% -$213 ﹤0.01% 587
2026
Q1 		$2.71K Buy
1,272
+153
+14% +$364 ﹤0.01% 619
2025
Q4 		$2.72K Buy
+1,119
New +$3.96K ﹤0.01% 640

Other funds holding BDTX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Ritholtz Wealth Management
Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

GF Fund Management's BDTX Position: Q3 2026 in Review

GF Fund Management increased its Black Diamond Therapeutics (BDTX) stake by 8.9% in Q3 2026, buying an estimated $206 and bringing the position to 1,290 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #596.

GF Fund Management first reported a position in BDTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $2.72K in Q4 2025. 45 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • GF Fund Management held 1,290 shares of Black Diamond Therapeutics worth $2.43K as of Q3 2026.
  • GF Fund Management bought 105 Black Diamond Therapeutics shares in Q3 2026, an estimated $206.
  • Black Diamond Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #596 holding.
  • GF Fund Management first reported a position in Black Diamond Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • GF Fund Management's Black Diamond Therapeutics position peaked at $2.72K in Q4 2025.
  • 45 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.